ORENITRAM Drug Patent Profile

Which patents cover Orenitram, and what generic alternatives are available?

Orenitram is a drug marketed by United Therap and is included in one NDA. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has fifty-nine patent family members in eight countries.

The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the treprostinil diolamine profile page.

DrugPatentWatch^® Generic Entry Outlook for Orenitram

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 15, 2028. This may change due to patent challenges or generic licensing.

There have been ten patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ORENITRAM

International Patents:	59
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	24
Clinical Trials:	7
Patent Applications:	116
Drug Prices:	Drug price information for ORENITRAM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORENITRAM
What excipients (inactive ingredients) are in ORENITRAM?	ORENITRAM excipients list
DailyMed Link:	ORENITRAM at DailyMed

See drug prices for ORENITRAM

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ORENITRAM

Constraining patent/regulatory exclusivity:

8,497,393

NDA:

203496

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ORENITRAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lung Biotechnology PBC	Phase 4
United Therapeutics	Phase 4
Bial - Portela C S.A.	Phase 1

See all ORENITRAM clinical trials

Pharmacology for ORENITRAM

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

Paragraph IV (Patent) Challenges for ORENITRAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ORENITRAM	Extended-release Tablets	treprostinil diolamine	0.125 mg and 5 mg	203496	1	2020-12-28
ORENITRAM	Extended-release Tablets	treprostinil diolamine	0.25 mg and 1 mg	203496	1	2016-05-19
ORENITRAM	Extended-release Tablets	treprostinil diolamine	2.5 mg	203496	1	2015-12-24

US Patents and Regulatory Information for ORENITRAM

ORENITRAM is protected by ten US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,497,393.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No	9,393,203		Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No	8,349,892		Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No	9,593,066			Y

Expired US Patents for ORENITRAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-004	Dec 20, 2013	9,278,901
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-004	Dec 20, 2013	7,544,713
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016	7,544,713

International Patents for ORENITRAM

When does loss-of-exclusivity occur for ORENITRAM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

European Patent Office

Japan

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORENITRAM around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2710205
China	101903324
China	103274926

ORENITRAM (treprostinil) Market Dynamics and Financial Trajectory: Exclusivity, Competitive Risk, and Revenue Path

Last updated: June 2, 2026

ORENITRAM (treprostinil) is an oral prostacyclin pathway therapy for pulmonary arterial hypertension (PAH). The product’s financial trajectory is driven by (1) prostacyclin class competition and dosing/titration dynamics, (2) patent and exclusivity cliffs around treprostinil formulations, and (3) the expansion of PAH treatment algorithms that increasingly favor combination therapy. In the US, ORENITRAM’s commercial outlook is also shaped by the Orange Book and Paragraph IV generic risk for oral treprostinil products, plus payer pressure and migration toward branded or semi-branded alternatives within the prostacyclin class.

ORENITRAM revenue trends and sales drivers: How has treprostinil oral performance evolved?

ORENITRAM’s market dynamics track two variables that move faster than baseline PAH incidence: adoption patterns for oral prostacyclin therapy and payer-driven formulary design. Historically, ORENITRAM captured patients looking to avoid parenteral prostacyclins, but its uptake depends on titration tolerability, total dose achieved, and real-world adherence to frequent dose adjustments early in therapy.

Key commercial drivers

• Oral administration advantage: reduces infusion logistics relative to IV prostacyclin analogs and lowers administration burden versus subcutaneous regimens.
• Titration and GI tolerability: nausea, diarrhea, jaw pain, headache, and flushing influence persistence and dose escalation speed, which in turn affect revenue per patient.
• PAH risk stratification and combination therapy: many patients receive background endothelin receptor antagonists and/or PDE-5 inhibitors plus prostacyclin therapy, pushing ORENITRAM into combination pathways rather than monotherapy in practice.
• Payer pressure and step edits: coverage for high-cost oral specialty drugs often depends on documentation of PAH severity and prior therapy failures.

Commercial performance structure (how revenue typically forms)

• New starts: influenced by guideline-aligned prostacyclin timing and the center’s prescribing norms.
• Dose ramp: influences average selling price per patient month.
• Persistence: discontinuation from GI adverse events or insufficient response reduces lifetime value.
• Switching within class: patients may move to other prostacyclin delivery systems (including IV or SC treprostinil) if symptom control or tolerability is better.

What patents protect ORENITRAM (treprostinil) and how strong is the patent estate for oral treprostinil?

A complete patent estate analysis requires Orange Book and litigation-level mapping for the specific ORENITRAM NDA listing(s) and all listed patents tied to marketed strengths, dosage forms, and approved labeling indications. Under the constraints here, a full and accurate estate build cannot be produced from the information in the prompt.

Key point for business planning

• For branded oral PAH prostacyclin therapies, the patent landscape typically spans:
  • composition-of-matter for treprostinil derivatives/formulations (where applicable),
  • method-of-use claims for PAH treatment regimens,
  • formulation and sustained-release mechanism claims for oral dosing,
  • manufacturing/controlled-release process claims.

Without NDA-specific patent numbers, claim sets, filing dates, and expiration terms tied to ORENITRAM’s Orange Book entries, any expiration or litigation assertions would be incomplete.

When does ORENITRAM lose exclusivity? What is the Orange Book status of treprostinil oral?

A precise exclusivity timeline depends on:

• Orange Book patent listing identifiers,
• patent expiration dates (including pediatric extensions),
• regulatory exclusivities (NCE/3-year/5-year where relevant), and
• any period-of-exclusivity tied to specific manufacturing changes or supplements.

The prompt does not include ORENITRAM’s Orange Book listing data, so a complete exclusivity schedule cannot be stated accurately.

How many competitors are targeting oral treprostinil (ORENITRAM) and what generic entry risks exist?

Generic entry risk for ORENITRAM depends on whether:

• there are ANDA applicants challenging listed patents via Paragraph IV,
• the challenge is to core listed patents tied to treprostinil oral formulation and/or method-of-use,
• the FDA regulatory pathway supports bioequivalence for the specific extended-release profile.

Without the Orange Book listing table (patent numbers and status) and any ANDA litigation docket results, the count of competitors and the probability-weighted entry risk cannot be validated.

What Paragraph IV challenges affect ORENITRAM and how does patent litigation affect launch timing?

Paragraph IV litigation affects market timing through:

• automatic 30-month stay (if conditions are met),
• injunction outcomes,
• settlement terms that can include launch dates and revenue-sharing/authorized generic windows.

The prompt provides no litigation records, case captions, district courts, or settlement terms. A docket-backed analysis cannot be produced.

ORENITRAM vs other PAH prostacyclin therapies: How does treprostinil oral compare with IV or inhaled options?

ORENITRAM competes inside the prostacyclin pathway against:

• parenteral treprostinil (IV and SC),
• prostacyclin pathway agents with different delivery systems (including inhaled options),
• broader combination regimens that delay prostacyclin initiation or substitute for it in some risk profiles.

How ORENITRAM typically compares in payer and patient decisioning

• Patient preference: oral is often favored if tolerability is manageable.
• Clinical center practice: dosing protocols for oral treprostinil differ across PAH centers and influence adoption.
• Dosing intensity: oral titration can require more frequent adjustments during early therapy.
• Total prostacyclin exposure: if oral titration cannot reach target dose due to side effects, prescribers may switch to IV/SC for tighter exposure control.

Financial implications

• If guideline and center practice shift prostacyclin use earlier or later, the oral market can either expand (more starts) or contract (shorter time-on-drug or substitution).
• Any increase in substitution to parenteral routes reduces oral patient share even if the prostacyclin category expands.

What delivery-formulation factors drive ORENITRAM market share: does tolerability shape persistence and revenue?

For oral sustained/sustained-like dosing in PAH, market share is highly sensitive to:

• GI tolerability profile and how quickly patients can reach doses that produce meaningful hemodynamic and symptomatic improvements,
• adherence, which can be impaired by nausea/diarrhea and the need for titration,
• management of breakthrough symptoms and prostacyclin-related adverse effects.

Financial linkage

• Early discontinuation reduces revenue concentration risk.
• Dose escalation speed affects average revenue per patient month.
• Real-world tolerability affects physician comfort, influencing new start volumes.

ORENITRAM financial trajectory by scenario: What revenue path happens under base case, downside, or accelerated competitive pressure?

A scenario model requires actual baseline revenue, share, and competitor mix. The prompt does not include those inputs, so a quantified scenario forecast cannot be produced.

Non-quantified scenario drivers that directly affect revenue trajectory

• Base case: stable persistence, continued use as an oral prostacyclin option in patients with manageable tolerability and payer approval pathways.
• Downside: reduced starts due to formulary restrictions, slower titration uptake, or increased substitution to other prostacyclin delivery methods.
• Accelerated competitive pressure: generic entry or authorized generics in the oral treprostinil space, combined with payer switching and higher discounting.

FDA status and regulatory milestones: How do approvals and labeling changes influence ORENITRAM commercial performance?

Regulatory milestones influence commercialization through:

• approved indications and labeled patient eligibility,
• changes to dosing regimens and titration language,
• new manufacturing changes that can enable supply stability or reduce cost.

The prompt does not provide FDA approval dates, supplement history, or labeling updates tied to ORENITRAM, so an accurate milestone calendar cannot be created.

Key legal and commercial inflection points: What settlement agreements and exclusivity events matter for ORENITRAM?

Settlement agreements can determine:

• timing of generic launch,
• whether an authorized generic enters early,
• the scope of patent carve-outs by product strength or dosing form.

No settlement terms or dockets are included in the prompt, so a litigation settlement map cannot be provided.

Where does ORENITRAM stand in the PAH competitive landscape by channel: hospitals, specialty pharmacies, and payers?

ORENITRAM’s commercialization relies on specialty channel economics:

• specialty pharmacy dispense volumes,
• payer prior authorization and patient support programs,
• center-based prescribing and nurse-led titration services.

Channel dynamics that affect net sales

• Wholesale acquisition vs net price: discounts and rebates often move with payer tiers and utilization management.
• Prior authorization friction: can suppress new starts and lead to payer churn.
• Patient support: can improve persistence by supporting titration and side-effect management.

Key Takeaways

• ORENITRAM’s commercial path is driven by oral prostacyclin adoption, GI tolerability and titration performance, and payer coverage mechanics.
• Financial trajectory is sensitive to substitution within the prostacyclin class and PAH combination-treatment norms.
• A complete, decision-grade view of exclusivity timelines, Paragraph IV risk, and patent strength requires ORENITRAM’s NDA-specific Orange Book and litigation data, which is not present in the prompt.

FAQs

1. How do payer step edits for oral PAH prostacyclins typically affect ORENITRAM patient starts?
2. What real-world factors determine persistence on oral treprostinil versus IV or SC treprostinil?
3. How do oral treprostinil dosing titration protocols influence average dose achieved and revenue per patient?
4. What types of patents (formulation, method-of-use, manufacturing) most commonly block generic oral treprostinil entry?
5. What settlement structures most often shape generic launch timing for branded specialty oral drugs in PAH?

References

1. (No sources were provided in the prompt.)